跳至主要内容
临床试验/PACTR202107709749875
PACTR202107709749875招募中4 期

A Randomized Controlled Trial Assessing the Efficacy and Safety Profile of Oral Ziliv Among Patients with Hepatic Disease Attending the Gastrointestinal Clinic of the Lagos University Teaching Hospital, Idi-Araba

Zifam Pinnacle Nigeria Ltd0 个研究点目标入组 100 人开始时间: 2021年6月13日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
All

入选标准

  • 1. All consenting adults (male or female) subjects aged 18years and above.
  • 2. All subjects with elevated alanine aminotransferase (ALT) enzyme levels of at ;least 1.5 times upper limit normal.

排除标准

  • 1. Subjects less than 10years old.
  • 2. Hepatic malignancies (primary or secondary).
  • 3. Terminally ill patients.
  • 4. Patients with history of advanced chronic kidney disease or on hemodialysis.
  • 5. Patients already on other hepatic-tonic supplements
  • 6. Patients who refuse to give to give consent.
  • 7. Pregnant or breastfeeding mothers.

研究者

发起方
Zifam Pinnacle Nigeria Ltd

相似试验